Neurocrine Biosciences Shifts Strategy After Luvadaxistat Trial
Neurocrine Biosciences Inc. (NASDAQ: NBIX) has made revisions to its strategic approach following the outcomes of the ERUDITE phase two clinical trial involving luvadaxistat (NBI-1065844). This investigational treatment aimed at addressing cognitive impairment in schizophrenia did not achieve its primary goal, prompting the company to rethink its direction.
Challenges Encountered in the ERUDITE Study
The clinical trial encountered substantial challenges, failing to replicate the beneficial cognitive outcomes that were seen in the earlier INTERACT study. Variability in cognitive measures across the participants and imbalanced baseline characteristics among subjects may have played a role in this outcome.
Learnings from Previous Research
Previously, the INTERACT study had shown encouraging results. A 50 mg dose of luvadaxistat brought about statistically significant improvements in cognitive performance, as measured by the Brief Assessment of Cognition in Schizophrenia (BACS) and metrics from the Schizophrenia Cognition Rating Scale (SCoRS).
Conclusion to Development of Luvadaxistat
In light of the unsatisfactory findings, Neurocrine has opted to halt further development of luvadaxistat. The company now plans to redirect its efforts towards NBI-1117568 and NBI-1065845, which are in development for schizophrenia and major depressive disorder, respectively.
Positive Indicators for NBI-1117568
Recent topline results from the phase one study of NBI-1117568 indicated its potential, revealing an average reduction of 18.2 points on the Positive and Negative Syndrome Scale (PANSS) after six weeks at a 20 mg once-daily dosage, compared to a 10.8-point decrease in the placebo group. These findings enhance confidence in the candidate's effectiveness and reflect the company's ongoing commitment to developing effective therapies for mental health disorders.
Looking Ahead: Growth Prospects
Analysts are optimistic about the growth trajectory for the company, especially with the expanding Ingrezza portfolio and the planned launch of crinecerfont to address congenital adrenal hyperplasia (CAH). With key dates on the horizon for late 2024, Neurocrine's future initiatives are set to potentially create further value in the biopharmaceutical sector.
Stock Performance Snapshot
Currently, shares of Neurocrine Biosciences have seen a modest increase of 0.82%, trading at around $122.27. This reflects the market's response during the transitional phase the company is undergoing.
Frequently Asked Questions
What prompted the decision to discontinue luvadaxistat?
The clinical trial did not fulfill its primary endpoint, leading to questions about its effectiveness in treating cognitive impairment associated with schizophrenia.
What are the new areas of focus for Neurocrine following luvadaxistat?
Neurocrine is concentrating on developing NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder.
What outcomes were observed in the previous INTERACT study?
The INTERACT study provided statistically significant improvements in cognitive measures, which had generated optimism regarding the potential of luvadaxistat at that time.
How has the stock market reacted to Neurocrine’s recent developments?
Neurocrine's shares have experienced a slight rise, indicating some level of investor confidence despite the hurdles faced.
What are the upcoming milestones for Neurocrine?
Expected milestones include the progress of crinecerfont for CAH, with key dates anticipated for late 2024.
